SHATTUCK LABS INC (STTK) Stock News
NASDAQ:STTK - Nasdaq - US82024L1035 - Common Stock - Currency: USD
STTK Latest News, Press Relases and Analysis
Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights
– Company advances SL-325 program with an IND filing expected in the third quarter of 2025 – – Cash balance of approximately $60.9 million as of March 31,...
Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights
Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference
AUSTIN, TX and DURHAM, NC, April 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the...
Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference
Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights
– Presented preclinical non-human primate (NHP) data at the 20th Congress of European Crohn’s and Colitis Organization in Inflammatory Bowel Diseases 2025...
Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights
Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn’s and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025
AUSTIN, TX & DURHAM, NC, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the...
Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn’s and Colitis Congress
AUSTIN, TX and DURHAM, NC, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the...
Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn’s and Colitis Congress
Shattuck Labs Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
Shattuck Labs Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
AUSTIN, TX and DURHAM, NC, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the...
Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2025
AUSTIN, TX and DURHAM, NC, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the...
Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2025
Shattuck Labs Announces Participation in Upcoming December Conferences
AUSTIN, TX and DURHAM, NC, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the...
Shattuck Labs Announces Participation in Upcoming December Conferences
Shattuck Labs Reports Third Quarter 2024 Financial Results and Recent Business Highlights
– Announced development of SL-325, a first-in-class antagonist antibody to DR3, the receptor for TL1A; IND filing expected in Q3'2025 – – Cash...
Shattuck Labs Reports Third Quarter 2024 Financial Results and Recent Business Highlights
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Shattuck Labs, Inc. - STTK
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Shattuck Labs, Inc. ("Shattuck" or the "Company") (NASDAQ: STTK). Such...
STTK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Shattuck Labs, Inc. and Encourages Investors to Contact the Firm
STTK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Shattuck Labs, Inc. and Encourages Investors to Contact the Firm
STTK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Shattuck Labs, Inc. and Encourages Investors to Contact the Firm
/PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Shattuck Labs, Inc....